Pargyline

Research use only, not for human use.

Pargyline is an irreversible non-selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 11.52 nM and for MAO-B is 8.2 nM) .

Pargyline is an irreversible non-selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 11.52 nM and for MAO-B is 8.2 nM) .(In Vitro):Pargyline (0.5-2 mM; 24-120 hours; LNCaP-LN3 cells) treatment inhibits the proliferation of prostate cancer cells in a time- and dose-dependent manner.Pargyline (0.5-2 mM; 24-48 hours; LNCaP-LN3 cells) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner.Pargyline (0.5 mM; 24 hours; LNCaP-LN3 cells) treatment increases the apoptotic cells.Pargyline (2 mM; 48 hours; LNCaP-LN3 cells) treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression.(In Vivo):Pargyline (10 mg/kg; iv) treatment induces a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats.A low dose of Pargyline (200 μg; icv) injected directly into the brain lowered arterial pressure. The hypotensive action of Pargylline in SHR appears to be the consequence of Norepinephrine accumulating at an inhibitory α-adrenoceptor in brain.

Pargyline (0.5-2 mM; 24-120 hours; LNCaP-LN3 cells) treatment inhibits the proliferation of prostate cancer cells in a time- and dose-dependent manner.Pargyline (0.5-2 mM; 24-48 hours; LNCaP-LN3 cells) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner.Pargyline (0.5 mM; 24 hours; LNCaP-LN3 cells) treatment increases the apoptotic cells.Pargyline (2 mM; 48 hours; LNCaP-LN3 cells) treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression. Cell Proliferation Assay Cell Line:LNCaP-LN3 cells Concentration:0.5 mM, 1 mM, 1.5 mM or 2 mM Incubation Time:24 hours, 48 hours, 72 hours, 96 hours or 120 hours Result:Inhibited the proliferation of prostate cancer cells in a time- and dose-dependent manner.Cell Cycle Analysis Cell Line:LNCaP-LN3 cells Concentration:0.5 mM, 2 mM Incubation Time:24 hours, 48 hours Result:The S phase ratio of the cells was decreased, while their G1 phase ratio was increased. Apoptosis Analysis Cell Line:LNCaP-LN3 cells Concentration:0.5 mM Incubation Time:24 hours Result:Increased the apoptotic cells.Western Blot AnalysisCell Line:LNCaP-LN3 cells Concentration:2 mM Incubation Time:48 hours Result:Induced an increase of cytochrome c and a decrease of caspase-3.

Pargyline (10 mg/kg; iv) treatment induces a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. A low dose of Pargyline (200 μg; icv) injected directly into the brain lowered arterial pressure. The hypotensive action of Pargylline in SHR appears to be the consequence of Norepinephrine accumulating at an inhibitory α-adrenoceptor in brain.

Pargyline | Eudatin

Metabolic Enzyme/Protease

MAO

MAO

Neurological Disease

——

555-57-7

159.23

C11H13N

>98% (HPLC)

Water: 10 mM

C#CCN(C)CC1=CC=CC=C1

Benzenemethanamine, N-methyl-N-2-propynyl-

(-20℃)

With Ice Pack

≥ 2 years